Effect of Guda-Haritaki(vardhamana krama) in the management of Yakritjanya jalodara with special reference to Ascites of Hepatic Cirrhosis origi
Phase 2
- Conditions
- Health Condition 1: K740- Hepatic fibrosis
- Registration Number
- CTRI/2024/07/070171
- Lead Sponsor
- Government Akhandanand Ayurveda College Ahmedabad
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients having ascites due to Hepatic Cirrhosis origin.
2.Chronicity less than 1 year.
3.Uncomplicated cases of Yakritjanya Jalodara.
4.Patients willing to participate in trial.
Exclusion Criteria
1.Hb less than 5 gm per dl
2.Pancreatic origin cirrhosis
3.AIDS
4.Congestive Cardiac Failure, Congestive Pericarditis, Other Cardiac disorders
5.T.B.
6.Nephrotic Syndrome
7.Grade 4 prolapsed hemorrhoid
8.Carcinoma
9.Hepatic encephalopathy
10.Diabetic ketoacidosis
11.Hepatitis B and Hepatitis C
12.Acute and Chronic Renal Failure
13.Acute pancreatitis
14.History of Recurrent Gastric & Esophageal Variceal Rupture & Hematemesis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method It is expected that the trial drugs will break the pathogenesis of Yakritjanya Jalodara and thus will be effective in the management of Yakritjanya Jalodara(Ascites of Hepatic cirrhosis origin) by give relief in subjective parameter like Distention of abdomen,Pedal edema,Anorexia,Weakness,Nausea and vomiting,Respiratory distress and objective parameters like AST, ALT, Serum bilirubin, serum alkaline phosphatase, A:G ratio, PT/INR.Timepoint: 40 Days
- Secondary Outcome Measures
Name Time Method The drug will improve the quality of life & thus will act as disease-modifying agent for Yakritjanya Jalodara(Ascites of Hepatic cirrhosis origin) by restoring normal function of liver, improve digestion, provide relief in generalised weakness, edema etc symptoms.Timepoint: 42 Days